A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 [eprotirome] as Add on to Statin Treatment in Patients With Dyslipidemia.

Trial Profile

A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 [eprotirome] as Add on to Statin Treatment in Patients With Dyslipidemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2012

At a glance

  • Drugs Eprotirome (Primary)
  • Indications Dyslipidaemias; Hypercholesterolaemia; Lipid metabolism disorders
  • Focus Therapeutic Use
  • Sponsors Karo Bio
  • Most Recent Events

    • 11 Mar 2010 Results were published in the New England Journal of Medicine (NEJM), according to a Karo Bio media release.
    • 04 Aug 2008 Status changed from in progress to completed, as reported by Karo Bio in a media release.
    • 17 Jan 2008 Status changed to in progress, in accordance with media release 9084370.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top